Posdinemab is part of a broader attempt by Johnson & Johnson to crack tau. (leremy/iStock/Getty Images Plus) Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has ...

Once dismissed as less effective, the vaccine now seems to be preventing infections and illness about as well as the two mRNA options. By Apoorva Mandavilli Roughly 17 million Americans received the ...

Several companies have presented compelling data from multiple myeloma studies at the 2026 American Society of Clinical Oncology (ASCO) meeting. Data was announced by both Bristol Myers Squibb (BMS) ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...